RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07178795, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed advanced or metastatic non-squamous non-small cell lung cancer;

    Inclusion criterion 4

    HER2 functional mutation confirmed by a central laboratory;

    Inclusion criterion 5

  3. Toxicity from previous anti-tumor treatments has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

    Inclusion criterion 9

    Previous treatment with HER2-targeted therapy or ADC drugs with camptothecin derivatives as the toxin;

    Exclusion criterion 4

  4. ECOG performance status score of 0 or 1;

    Inclusion criterion 8

  5. Must have at least one measurable target lesion as defined by RECIST v1.1;

    Inclusion criterion 7

  6. Diagnosis of other primary malignancies within 5 years prior to the first dose;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07178795, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • Age at the time of signing the informed consent form is ≥18 years and ≤75 years, regardless of gender;
  • Expected survival time ≥12 weeks;
  • Histologically or cytologically confirmed advanced or metastatic non-squamous non-small cell lung cancer;
  • HER2 functional mutation confirmed by a central laboratory;
  • Provide the most recent tumor tissue meeting the requirements for biomarker testing by the central laboratory;
  • Must have at least one measurable target lesion as defined by RECIST v1.1;
  • ECOG performance status score of 0 or 1;
  • Toxicity from previous anti-tumor treatments has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
  • Organ function levels must meet the requirements;
  • For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days prior to the start of treatment, and the serum pregnancy test must be negative. They must not be breastfeeding. All enrolled patients (regardless of gender) should take adequate and highly effective contraceptive measures throughout the treatment period and for 7 months after the end of treatment.

Exclusion Criteria:

  • Having undergone surgical treatment, radical radiotherapy, immunotherapy, etc., within 4 weeks prior to the first dose or within 5 half-lives;
  • Pathological findings indicating non-small cell carcinoma containing small cell carcinoma components and sarcomatoid carcinoma;
  • Concurrent presence of other driver gene mutations for which targeted drug therapy is available and approved for NSCLC indications;
  • Previous treatment with HER2-targeted therapy or ADC drugs with camptothecin derivatives as the toxin;
  • History of severe cardiovascular or cerebrovascular diseases within the past 6 months prior to screening;
  • Concurrent pulmonary diseases leading to severe impairment of lung function;
  • History of ILD/interstitial pneumonia requiring steroid treatment or current diagnosis of ILD/interstitial pneumonia;
  • Prolonged QT interval, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
  • Diagnosis of other primary malignancies within 5 years prior to the first dose;
  • Newly developed deep vein thrombosis within 14 days prior to screening;
  • Hypertension poorly controlled by antihypertensive medications;
  • Patients with central nervous system (CNS) metastases, carcinomatous meningitis (leptomeningeal metastases), and/or spinal cord compression;
  • Patients with a history of severe allergies to any excipients or components of the investigational drug;
  • History of autologous or allogeneic stem cell transplantation or organ transplantation;
  • Positive human immunodeficiency virus antibody, active hepatitis B virus infection, liver cirrhosis, or hepatitis C virus infection;
  • Occurrence of severe infections within 4 weeks prior to the first use of the investigational drug;
  • Patients with significant serous cavity effusion, symptomatic serous cavity effusion, or poorly controlled serous cavity effusion;
  • Systemic corticosteroid treatment with >10 mg/d prednisone or equivalent prior to randomization;
  • Presence of severe neurological or psychiatric disorders;
  • Subjects with clinically significant bleeding or obvious bleeding tendencies within 4 weeks prior to signing informed consent;
  • Conditions such as intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea;
  • Subjects planning to receive or having received live vaccines within 28 days prior to the first dose;
  • Presence of other severe physical or laboratory abnormalities, poor compliance, or any other factors that may increase the risk of participation in the study, interfere with study results, or make the patient unsuitable for participation in the study as determined by the investigator.

Quoted from ClinicalTrials.gov, NCT07178795, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07178795, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07178795